Academia
Academia

Noticias del mercado & perspectivas

Anticípate a los mercados con perspectivas de expertos, noticias y análisis técnico para guiar tus decisiones de trading.

Shares and Indices
Barrick Gold beats Q2 estimates – sends the stock price higher

Barrick Gold Corporation (GOLD) reported its latest financial results before the market open in the US on Monday. One of the world’s largest gold producers reported revenue of $2.874 billion vs. $1.178 billion expected. The Canadian company reported earnings per share of $0.24 per share for Q2, also beating analyst estimate of $0.23 per share. ''A stronger Q2 performance across the portfolio has kept Barrick on course to achieve its annual gold and copper production guidance while continuing to progress its key growth projects.'' ''Gold production for the quarter was higher than Q1 at 1.04 million ounces — driven mainly by Carlin and Turquoise Ridge in Nevada, Veladero in Argentina, and Bulyanhulu and North Mara in Tanzania — and is expected to grow further in the second half of the year.

Copper production came to 120 million pounds.'' ''A dividend of $0.20 per share was declared for the quarter on the back of the strong operating performance and net cash of $636 million. During the quarter, Barrick repurchased $182 million in shares under the $1 billion share buyback scheme introduced earlier this year,'' the company wrote in a press release. Barrick Gold Corporation (GOLD) chart The stock price rose on Monday, up by around 5% at $16.27 per share.

Here is how the stock has performed in the past year: 1 month -4.18% 3 months -24.29% Year-to-date -14.37% 1 year -20.87% Barrick Gold price targets Barclays $25 Jefferies $24 UBS $34 Deutsche Bank $35 Credit Suisse $22 Barrick Gold Corporation is the 608 th largest company in the world with a market cap of $29.08 billion. You can trade Barrick Gold Corporation (GOLD) and many other stocks from the NYSE, NASDAQ, HKEX and the ASX with GO Markets as a Share CFD. Sources: Barrick Gold Corporation, TradingView, MarketWatch, Benzinga, CompaniesMarketCap

Klavs Valters
August 9, 2022
Shares and Indices
Moderna Q2 results announced – the stock gets a boost

Moderna Inc. (MRNA) reported its Q2 financial results before the opening bell on Wall Street on Wednesday. The American biotechnology company posted results that beat expectations, sending the stock higher at the open. The company reported revenue of $4.749 billion for the quarter vs. $4.097 billion expected.

Earnings per share reported at $5.24 per share vs. $4.58 per share estimate. "Today's earnings represent a strong second quarter performance, with $10.8 billion in revenue for the first half of the year. We continue to have advance purchase agreements for expected delivery in 2022 of around $21 billion of sales. Given our strong financial position and commercial momentum, we are announcing today that the Board of Directors has approved a new share repurchase program for $3 billion," Stéphane Bancel, CEO of the company said in a press release. "Despite the slowing economy and challenges in the biotech industry, Moderna is in a unique position: a platform to drive scale and speed in research of new medicines, a strong balance sheet with $18 billion of cash and an agile, mission-driven team of over 3,400 people and growing.

We will continue to invest and grow as we have never been as optimistic about Moderna's future. Right now, we have four infectious disease vaccines in Phase 3 trials, and later this year, we expect important data from proof-of-concept studies in rare diseases and immuno-oncology. Our teams are actively working to prepare these new product launches to help patients and drive growth.

This is an exciting time for Moderna as we continue to see significant scientific and business momentum," Bancel concluded. Moderna Inc. (MRNA) chart The stock was up by around 14% on Wednesday at $187.11 a share. Here is how the stock has performed in the past year: 1 Month +16.71% 3 Month +20.11% Year-to-date -26.68% 1 Year -55.56% Moderna price targets SVB Leerink $77 Piper Sandler $214 Morgan Stanley $199 Deutsche Bank $155 UBS $221 B of A Securities $180 Moderna is the 180 th largest company in the world with a market cap of $74.57 billion.

You can trade Moderna Inc. (MRNA) and many other stocks from the NYSE, NASDAQ, HKEX and the ASX with GO Markets as a Share CFD. Sources: Moderna Inc., TradingView, MetaTrader 5, Benzinga, CompaniesMarketCap

Klavs Valters
August 3, 2022
Central Banks
RBA preview – likely 50bp hike incoming

Todays RBA policy meeting is expected by most analysts to result in a 50bp hike as the bank tries to play catch up and get on top of elevated inflation figures. The slightly lower Q2 CPI figures released last week has seen futures markets price out what was earlier feared could be a 75bp supersized move, a 50bp hike would see the bank able to respond further in September should the Wage price index data due on 17 August show an alarming increase in wage costs. A 50bp hike today will bring the cash rate up to 1.85% which means we would be looking at least a further 65bp of hikes coming to bring the cash rate to the neutral level of 2.5% indicated by RBA governor Lowe at the last RBA policy meeting.

Currently August rate futures are trading at an implied yield of 1.76%, pricing in a rise of 41bp which indicates traders are giving around an 80% chance of a 50bp hike. Bond traders are rarely wrong when this much is priced in so I expect a 50bp move today with the accompanying statement giving clues to Septembers meeting where it’s looking so far as a toss up between 25 or 50bp. Expected AUD reaction If a 50bp hike is announced, the most likely course in the short term for the AUD will be an initial spike up due to the markets only pricing in 80%, then volatility as the algos read the statement, and more volatility as humans get through it.

Followed by a sustained move in either direction depending on how markets re-price after digesting what the RBA has released. Keep an eye on our Twitter page for instant reaction to the RBA announcement Also please join us on our live webinar of the RBA meeting and market reaction, register at the link below RBA Live Webinar

Lachlan Meakin
August 2, 2022
Shares and Indices
PayPal Q2 earnings results are here

PayPal Holding Inc. (PYPL) announced its latest financial results after the closing bell in the US on Tuesday. The US financial technology company reported revenue of $6.8 billion in Q2, topping Wall Street estimate of $6.778 billion. Earnings per share also beat analyst estimates for the quarter at $0.93 per share vs. $0.87 per share estimate. ''Our second quarter results were solid with currency neutral revenue and non-GAAP earnings growth exceeding expectations.

We continue to gain share as we execute across our key strategic initiatives, even as we drive operational efficiency across our business.'' Dan Schulman, President and CEO of PayPal said in a press release after the latest results. PayPal Holding Inc. (PYPL) chart Shares of PayPal were up by 1.20% at the close of trading on Tuesday $89.63. The stock rose by around 11% after better than expected Q2 results.

Here is how the stock has performed in the past year: 1 Month +20.47% 3 Month -1.19% Year-to-date -52.47% 1 Year -67.23% PayPal price targets Berenberg $145 Oppenheimer $101 Keybanc $100 Wells Fargo $97 JP Morgan $112 JMP Securities $100 RBC Capital $92 Piper Sandler $93 Truist Securities $80 Credit Suisse $95 Morgan Stanley $129 PayPal is the 118 th largest company in the world with a market cap of $103.79 billion. You can trade PayPal Holding Inc. (PYPL) and many other stocks from the NYSE, NASDAQ, HKEX and the ASX with GO Markets as a Share CFD. Sources: PayPal Holding Inc., TradingView, MetaTrader 5, Benzinga, CompaniesMarketCap

Klavs Valters
August 2, 2022
Shares and Indices
Pfizer tops estimates for Q2

Pfizer Inc. (PFE) reported its Q2 financial results before the market open in the US on Thursday. World’s third largest pharmaceutical company topped both revenue and earnings per share estimates for the quarter. The company reported revenue of $27.742 billion in Q2 (up 47% year-over-year) vs. $25.487 billion expected.

Earnings per share reported at $2.04 per share (up by 92% year-over-year) vs. $1.72 per share estimate. Dr. Albert Bourla, Chairman and CEO commented on the latest results: ''In multiple meaningful ways, we made significant progress this quarter on our strategies to bring value to our patients and shareholders, while also making commitments to prioritize the broader needs of the world, including those of the environment and our most vulnerable populations.

For example, we set an ambitious goal for ourselves to achieve the Net-Zero Standard for greenhouse gas emissions by 2040, ten years ahead of the timeline described in the standard. We also launched an initiative to help bring all of our current and future patented medicines and vaccines to the 1.2 billion people living in 45 lower-income countries around the world at not-for-profit prices, a first in the industry.'' ''Even while launching these initiatives to support a healthier, more equitable world, we remain equally committed to strong financial execution on behalf of our shareholders. In the second quarter, we recorded the largest amount of quarterly sales in our history.

We also presented potentially best-in-class data for etrasimod and announced the proposed strategic acquisition of Biohaven, both of which are closely tied to our purpose: Breakthroughs that change patients’ lives,'' Dr. Bourla concluded. Pfizer Inc. (PFE) chart Despite beating Wall Street expectations for Q2, shares of Pfizer were down by around 1% at $50.98 per share.

Here is how the stock has performed in the past year: 1 Month -2.82% 3 Month +0.87% Year-to-date -13.72% 1 Year +19.07% Pfizer price targets Morgan Stanley $49 Wells Fargo $55 Citigroup $57 B of A Securities $70 Goldman Sachs $51 Pfizer Inc. is the 27 th largest company in the world with a market cap of $285.76 billion. You can trade Pfizer Inc. (PFE) and many other stocks from the NYSE, NASDAQ, HKEX and the ASX with GO Markets as a Share CFD. Sources: Pfizer Inc., TradingView, MetaTrader 5, Benzinga, CompaniesMarketCap

Klavs Valters
July 29, 2022
Trading strategies
Psychology
Is it time to Capitalise on Short Squeezes?

Is it time to Capitalise on Short Squeezes ? Short Squeezes are one of the interesting price action patterns that can occur in the market. They can provide It can provide explosive momentum trading opportunities that can go on for days.

They can provide trading opportunities for scalpers, intraday, and swing traders. What actually is a short squeeze and why do they occur? To understand a short squeeze it is important to go back to the basics of trading and understand what an actual short is and why market participants go short on a product.

What is a short? A short is a position that a market participant takes when they expect the price of a market product to go down. This can include but is not excluded too, Securities, Commodities and Forex.

A trader may take a short position because they believe a company is overvalued, a currency will go down in value due to economic factors, to hedge or for a number of other reasons. Short positions can be taken in a range of ways, however, the most common method for shorting a CFD is quite simple. It involves borrowing units to sell with the short holder having to buy-back the units at a lower price and pocketing the difference.

Example A trader believes that company ABC is overvalued at $1.00 and decides to borrow 100 CFD units of ABC to short at $1.00 per CFD with a total value of $100. The price then falls to $0.50. The trader closes their position and buys back the CFDs at $50.

They are then able to pocket the difference of $50.00. The mechanics of a short squeeze. Due to the nature of a short position which requires a buying back of the stock to both close the position and lock in profit a trader will inevitably have to buy-back or close their position at some point.

This subsequently drives up the price. Most of the time in a trending market this process works without any issues. However, if the price stops falling and consolidates or to a stage where the market starts to see value in the price again, large short holders may decide to close out their position.

If big positions or institutions close all at once it can create an avalanche effect. Indicators of a short squeeze A stock, currency, or commodity that is highly shorted or is overextended to the sell side is often ripe for a squeeze. In addition, if the underlying asset is getting closer to an area of support or resistance it may show that the selling has dried up.

Shorters may then need to close their positions soon otherwise they risk holding losing positions If a stock is bottoming or basing it may indicate that buyers are beginning to take control of the price again. This shows that the asset has reached a point where it really can’t fall any further in price because buyers see too much value. A shift in the relative volume can indicate that either a big position is closing or buyers have found an area of value and that the price might be ready to reverse.

The large volume can also indicate that an institution is playing an active role in the price. It is usually good practice to follow where the big money is when trading. Squeezing in the current market A short squeeze can represent a great opportunity to profit for traders.

They can often be explosive moves and last for days. This means that whether you are a swing trader, day trader, or a scalper anyone can capitalise on a squeeze. In addition, with the current state of the market having one of its worst first half of the years in history, with bearish sentiment being very high.

The Nasdaq in particular and growth stocks in particular have seen their value smashed. As big short positions have been taken at some stage they will have to be closed and if the market can rally, then this phenomenon may become more regular. For instance the company ZIP a strong player in the Buy Now Player Sector had seen its share priced reduced to a fraction of its peak prior to just a few weeks ago.

However as seen in the chart below, a shift in volume was the first signal that the stock was about squeeze and shift strongly to the upside. In this instance, ZIP on the weekly chart saw a massive jump in volume, followed by an even larger jump in volume the following week. Importantly ZIP, according to (Shortman.com.au) had a short % of 7.34 on July 1 2022, prior to the breakout.

Looking at the daily chart underneath, the sheer volume of buying continued to get larger and larger which is indictive of a short squeeze as large positions began to close. The subsequent price action provided great consistent buying opportunities for traders.

GO Markets
July 29, 2022